Le Lézard
Classified in: Health
Subject: PER

Impopharma Inc. Strengthens Management Team and Board of Directors



TORONTO, Oct. 5, 2017 /PRNewswire/ -- Impopharma Inc. today announced the following organizational changes:

In his new role, Mr. Mayers will provide strategic leadership and assume responsibility for day-to-day operations of the organization. He brings 27 years of pharmaceutical experience; most recently as President and founder of Maycore Inc., a business development and consulting solutions company, and previously Managing Partner of Pharm Eng. Technologies. Prior to this, Mr. Mayers was President of WellSpring Pharma Services, where he managed strategic and operational aspects of the CDMO organization. Previously, Mr. Mayers was Vice President Manufacturing Operations at Purdue Pharma, where he managed significant facility expansions and engineered the launch and line extension of such major brands as Targin, Biphentin and OxyNEO. Mr. Mayers also has held leadership positions in Manufacturing, Quality, Research & Development, Operations, Project Management and Strategy for Apotex, Merck KGaA, Taro and SmithKline Beecham.

Mr. Mayers holds an Hons. BSc. Degree in Biological Sciences from the University of Guelph and an MBA from the Rotman School of Business, University of Toronto.

Dr. Odlaug, Impopharma's Executive Chairman, stated "David's extensive experience in the pharmaceutical industry, specifically in the areas of product development and analytical R&D coupled with his in-depth knowledge of the CDMO space make him the ideal person to help build out future."

David Brown joins Impopharma from Teva Ltd, where he was Director, R&D Program Management with responsibility for portfolio selection, project management and technical expertise. Previously, he was Director, Pharmaceutical Development. Dr. Brown began his career in the UK in respiratory drug development at Fisons Plc. After moving to Canada, he worked at RTP Pharma and Patheon Inc.

Dr. Brown holds an Hons. Bachelor of Pharmacy and a Ph.D. in Pharmaceutics from the School of Pharmacy, University of London, United Kingdom.

"We are pleased to announce, David Brown has assumed the role of Senior Director R&D overseeing all aspects of R&D including formulation, product development and analytical services," said Mr. Mayers. "Dr. Brown brings not only over 20 years of experience in project management and product development but his formulation experience in respiratory device products positions us well to serve our clients and develop future projects."

Wayne Kreppner was most recently President and Chief Operating Officer at Concordia International. Mr. Kreppner brings over 20 years of experience as a pharmaceutical operations and R&D executive. A co-founder and former Vice-President of Product Development at Trimel Pharmaceuticals, Mr. Kreppner was responsible for all scientific operations including R&D, clinical development, manufacturing and supply chain. From 1997 to 2008 Mr. Kreppner held various senior roles in operations and regulatory affairs with Biovail Corporation.

Mr. Kreppner holds a Hons. B.Sc. degree in Biochemistry from the University of Western Ontario, an M.Sc. in Medical Science from McMaster University and an MBA from the Ivey School of Business, University of Western Ontario.

Dr. Odlaug noted that "Wayne Kreppner brings a proven track record of experience in the pharmaceutical industry and will further enhance our strategic leadership as a member of our Board."

About Impopharma

Impopharma is a well-resourced development and testing facility with an expert and experienced team located in Concord, Ontario, Canada that specializes in the development and testing of pulmonary and nasal drug delivery systems and ophthalmic, otic, and dermal products. Please visit
www.Impopharma.com.

Contact:
Impopharma Inc.
Vice President, Finance
Tel: (905) 760-0232
Vien Brewster

SOURCE Impopharma Inc.


These press releases may also interest you

at 08:03
VITALHUB CORP. (the "Company" or "VitalHub"), is pleased to announce that it has acquired Clarity Healthcare Solutions and other selected assets of Clarity Health Inc. ("Clarity"), such assets having previously represented approximately $200,000 in...

at 08:00
The "Global Vial Cap Sealing Machines Market 2018-2022" report has been added to ResearchAndMarkets.com's offering. The global vial cap sealing machines market to grow at a CAGR of 4.89% during the period 2018-2022. Global Vial Cap Sealing...

at 08:00
Takara Bio USA, Inc. (TBUSA, formerly Clontech Laboratories, Inc.), a wholly owned subsidiary of Takara Bio Inc., is proud to announce that City of Hope has recently procured a SMARTer ICELL8 Single-Cell System to perform high-level studies involving...

at 07:59
Tabuk Pharmaceuticals Manufacturing Company ("Tabuk"), one of the leading pharmaceutical companies in the Middle East and North Africa region, has entered into an exclusive licensing and supply agreement with red otc development GmbH ("red otc") on...

at 07:12
Meagan Martin is known as the SheWolf and is widely considered to be the best female on the American Ninja Warrior circuit, having made it far into stage one of the National Finals two years in a row. The professional rock climber is also one of the...

at 06:49
kneat.com, inc. ("kneat.com", "Kneat", or the "Company") is pleased to announce that one of its customers, a leading US molecular diagnostics company, has increased its number of Kneat licenses by fifty percent. This growth is in response to the...




News published on 5 october 2017 at 17:15 and distributed by: